Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

99
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

28
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

43.1K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.1K
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

49
Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
49
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

108
Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
108
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

30
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
30

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Diagnostic approach for metabolic dysfunction associated steatotic liver disease].

La Revue du praticien·2026
Same author

Efficacy and Safety of Glecaprevir/Pibrentasvir in Participants with Chronic HCV Infection and Comorbidities or Multiple Concomitant Medications: An Integrated Analysis.

Infectious diseases and therapy·2026
Same author

HCV Cure: To Bridge the Gaps in the Care Continuum.

Journal of viral hepatitis·2026
Same author

In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus.

Cell reports·2025
Same author

Cystic fibrosis liver disease progression in the era of elexacaftor-tezacaftor-ivacaftor.

JHEP reports : innovation in hepatology·2025
Same author

Mortality risk in migrant and non-migrant individuals with chronic hepatitis B virus infection: a French hospital-based cohort study (ANRS CO22 HEPATHER).

BMC global and public health·2025

Related Experiment Video

Updated: May 5, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K

[Hepatitis C virus: 25 years-old, the end?].

Stanislas Pol1

  • 1Université Paris Descartes, Inserm U1016, unité d'hépatologie, hôpital Cochin APHP, 27, rue du Faubourg Saint-Jacques, 75014 Paris, France.

Medecine Sciences : M/S
|November 28, 2013
PubMed
Summary

Hepatitis C virus (HCV) treatment has advanced significantly with direct-acting antivirals (DAAs). New oral DAA combinations promise a revolution in HCV therapy, offering higher efficacy and improved patient outcomes.

Area of Science:

  • Hepatology and Viral Gastroenterology
  • Pharmacology and Drug Development
  • Infectious Diseases and Virology

Context:

  • Hepatitis C virus (HCV) infection treatment has evolved over two decades.
  • Initial treatments combined pegylated interferon-alfa and ribavirin, achieving limited sustained virologic response (SVR) rates.
  • Understanding the HCV lifecycle led to direct-acting antiviral (DAA) development targeting viral proteins.

Purpose:

  • To review the progression of HCV treatment strategies.
  • To evaluate the efficacy and safety of emerging DAA therapies.
  • To discuss the future landscape of HCV management with all-oral DAA regimens.

Summary:

  • First-generation oral DAAs combined with pegylated interferon-alfa/ribavirin showed improved SVR rates (75%).

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Experiment Videos

Last Updated: May 5, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

23.7K
A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

9.4K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
  • Second-generation DAAs are expected to further increase SVR (75-90%), enhance tolerance, shorten therapy, and reduce pill burden.
  • The next frontier involves all-oral DAA combinations poised to become the standard of care, with ongoing research in difficult-to-treat populations.

    • Impact:

    • DAA development represents a major advancement in HCV treatment.
    • Oral DAA combinations are anticipated to revolutionize chronic HCV management.
    • Further studies are needed to confirm efficacy in complex patient groups, including those with cirrhosis or co-infections.